Galantamine Disease Interactions
There are 5 disease interactions with galantamine.
Cholinesterase inhibitor (applies to galantamine) bradycardia
Major Potential Hazard, Moderate plausibility. Applicable conditions: Arrhythmias
Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block. Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities. Syncopal episodes have been reported in patients with and without cardiac abnormalities. Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.
Cholinesterase inhibitor (applies to galantamine) bronchospasm
Major Potential Hazard, Moderate plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease, Asthma
Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine. The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm. Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease. Monitoring respiratory function during dosage initiation and adjustment is recommended. Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress. Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium. However, the duration of action is longest for ambenonium and shortest for edrophonium. Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.
Cholinesterase inhibitor (applies to galantamine) PUD
Major Potential Hazard, Moderate plausibility. Applicable conditions: Peptic Ulcer
The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions. Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.
Galantamine (applies to galantamine) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
In patients with moderate hepatic impairment (Child-Pugh score of 7 to 9), the dosage of galantamine should generally not exceed 16 mg/day. The use of galantamine hydrobromide tablets in patients with severe hepatic impairment (Child-Pugh score of 10 to 15) is not recommended.
Galantamine (applies to galantamine) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
In patients with creatinine clearance of 9 to 59 mL/min, the dosage of galantamine should generally not exceed 16 mg/day. In patients with creatinine clearance less than 9 mL/min, the use of galantamine hydrobromide tablets is not recommended.
Galantamine drug interactions
There are 413 drug interactions with galantamine.
Galantamine alcohol/food interactions
There is 1 alcohol/food interaction with galantamine.
Report options
More about galantamine
- galantamine consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (15)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: cholinesterase inhibitors
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
